Evidence map›Paper›PMID 40001911›Full record

ReviewBiology2025

Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.

Lucas Fornari Laurindo, Otávio Augusto Garcia Simili, Adriano Cressoni Araújo, Elen Landgraf Guiguer, Rosa Direito, Vitor Engrácia Valenti, Vitor de Oliveira, Juliana Santos de Oliveira, José Luiz Yanaguizawa Junior, Jefferson Aparecido Dias and 6 more

Abstract readReview
In one paragraph

Review in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Unraveling the Effects ofInternational journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lucas Fornari LaurindoDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.ORCID 0000-0003-3159-0982
Otávio Augusto Garcia SimiliDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.
Adriano Cressoni AraújoDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.
Elen Landgraf GuiguerDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.
Rosa DireitoLaboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines, Universidade de Lisboa (iMed.ULisboa), Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal.ORCID 0000-0002-4143-4302
Vitor Engrácia ValentiAutonomic Nervous System Center, School of Philosophy and Sciences, São Paulo State University, Marília 17525-902, SP, Brazil.
Vitor de OliveiraDepartment of Biochemistry and Pharmacology, School of Medicine, New York Medical College, New York, NY 10595, USA.
Juliana Santos de OliveiraDepartment of Biochemistry and Pharmacology, School of Medicine, University of Miami, Coral Gables, FL 33146, USA.
José Luiz Yanaguizawa JuniorPostgraduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.
Jefferson Aparecido DiasPostgraduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.
Durvanei Augusto MariaDevelopment and Innovation Laboratory, Butantan Institute, São Paulo 05585-000, SP, Brazil.
Rose Eli Grassi RiciPostgraduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.
Manuela Dos Santos BuenoDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.
Kátia Portero SloanTexas Institute for Kidney and Endocrine Disorders, Lufkin, TX 75904, USA.
Lance Alan SloanTexas Institute for Kidney and Endocrine Disorders, Lufkin, TX 75904, USA.
Sandra Maria BarbalhoDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil.ORCID 0000-0002-5035-876X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melatonin is indispensable for the homeostasis of plants and animals. In humans, it can help prevent or be an adjuvant treatment for several diseases mainly related to the immune system, inflammation, and oxidative stress. Moreover, a melatonin-rich diet is linked to several health benefits, such as regulation of circadian rhythm, regulation of the immunological system, epilepsy control, delaying the aging process, and diminishing hormones related to cancer. This review aimed to show the effects of melatonin in diseases beyond its traditional use. The results showed it can present scavenging of free radicals, reducing inflammatory cytokines, and modulating the immune system. Moreover, it can improve insulin resistance, blood pressure, LDL-c, adipose tissue mass, adhesion molecules, endothelial impairment, and plaque formation. These effects result in neuro- and cardioprotection, improvement of liver diseases, rheumatoid arthritis, dermatitis, COVID-19, polycystic ovaries, and sepsis. We conclude that plant melatonin can benefit patients with many diseases besides sleep problems and neurodegeneration. Plant melatonin may be more cost-effective and present fewer adverse events than synthetic. However, more clinical trials should be performed to show adequate doses, formulation, and treatment time.

Indexed as

cancercardiovascular diseasesCOVID-19dysbiosismelatoninplantspolycystic ovary syndromerheumatoid arthritissepsis

Identifiers

PMID40001911
PMCPMC11851571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.